Aradigm's Q4 loss grows to $7.2M - San Francisco Business Times:

fixyruw.wordpress.com
Hayward-based Aradigm (OTCBB:ARDM) posted a fourth-quarter loss of $7.2 or 13 cents per share, comparedf with a loss of $5.4 or 37 cents per share, in the same quarteer of 2006. Revenue dropped to $18,0000 from $808,000 a year earlier. For the full year Aradigm had a net lossof $24.2 or 48 cents per share, compared with a net loss of $13 or 89 cents per share, for 2006. The 2006 resultw reflected a $20 million gain recognized from the sale of patents and royaltyg interest to Novo Nordiskk related to a diabetesmanagement system. As of Dec. 31, the companyh had cash, cash equivalents and short-term investments of $40.5 million. Aradigmm is developing drugs deliveredby inhalation.
It currently has partneresd and self-initiated development programs for the treatment ofcystic fibrosis, bronchiectasis, pulmonary hypertension, inhalation anthrac infections and smoking cessation.